Advanced search

Authors whose works are in public domain in at least one jurisdiction

List of works by Marc A Pfeffer

2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials

scientific article published in February 2018

2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials

scientific article published in March 2018

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease

scientific article published on 30 October 2009

Acute decline in renal function, inflammation, and cardiovascular risk after an acute coronary syndrome

scientific article published on 09 October 2009

Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial

scientific article

Adherence to medication according to sex and age in the CHARM programme

article

Albuminuria in chronic heart failure: prevalence and prognostic importance

scientific article published in August 2009

An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry

scientific article published in November 2004

Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved ⬇️

scientific article published on 18 December 2013

Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial

scientific article published on 26 June 2017

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

scientific article published on 01 September 2019

Angiotensin-converting-enzyme inhibition in stable coronary artery disease

scientific article published on 7 November 2004

Association between ADAMTS1 matrix metalloproteinase gene variation, coronary heart disease, and benefit of statin therapy

scientific article published on 3 January 2008

Association between mean systolic and diastolic blood pressure throughout the follow-up and cardiovascular events in acute myocardial infarction patients with systolic dysfunction and/or heart failure: an analysis from the High-Risk Myocardial Infar

scientific article published on 4 January 2018

Association of Heart Rate and Outcomes in a Broad Spectrum of Patients With Chronic Heart Failure

article

Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials.

scientific article published in January 2008

Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program

scientific article published on 27 April 2006

Baseline Characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)

article

Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial

scientific article published on 01 July 2018

Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme

scientific article published on 31 March 2010

Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF).

scientific article published on 17 January 2013

Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme

scientific article published on 5 November 2008

Body Mass Index and Prognosis in Patients With Chronic Heart Failure

article

C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).

scientific article published on 16 September 2016

C-reactive protein levels and outcomes after statin therapy

scientific article published in January 2005

Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy

scientific article

Cardiac structure and function, remodeling, and clinical outcomes among patients with diabetes after myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both

Cardiac-resynchronization therapy for the prevention of heart-failure events

scientific article published in September 2009

Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval

scientific article published on 5 July 2007

Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).

scientific article

Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial

scientific article

Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction

scientific article

Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM.

scientific article published on 21 December 2006

Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study.

scientific article published on 29 November 2004

Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).

scientific article published on 27 January 2009

Circumstances and outcomes of sudden unexpected death in patients with high-risk myocardial infarction: implications for prevention

scientific article published on 23 May 2011

Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme

article by Athar A. Badar et al published February 2015 in European Journal of Heart Failure

Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity).

scientific article published on 10 July 2013

Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program

scientific article published on 13 February 2006

Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program

scientific article

Cognitive function and anticoagulation control in patients with atrial fibrillation

scientific article

Comparison of renal function and cardiovascular risk following acute myocardial infarction in patients with and without diabetes mellitus

scientific article

Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure

scientific article published on 30 November 2017

Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors

scientific article published in March 2002

Corrigendum to ‘Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved’ [Eur J Heart Fail2014;16:33-40]

scholarly article published in European Journal of Heart Failure

Corrigendum to ‘Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial’ [Eur J Heart Fail2009;11:795-801]

scholarly article published in European Journal of Heart Failure

Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program

scientific article published on 07 October 2011

Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial

scientific article published in August 2009

Developing therapies for heart failure with preserved ejection fraction: current state and future directions

scientific article

Dual Renin-Angiotensin System Blockade in Heart Failure

ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD.

scientific article published on 7 June 2017

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial

scientific article

Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction

scientific article published on 19 November 2007

Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme

scientific article published in November 2004

Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program

scientific article published on 4 October 2004

Effect of clopidogrel added to aspirin in patients with atrial fibrillation

scientific article

Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT

scientific article published on 09 May 2016

Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction

article

Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF

scientific article published on 17 November 2019

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

scientific article published in September 2003

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

scientific article

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

scientific article

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

scientific article

Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure

scientific article published on 27 June 2005

Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme

scientific article published on 23 April 2010

Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in He

scientific article

Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes

article

Estimated glomerular filtration rate, inflammation, and cardiovascular events after an acute coronary syndrome

scientific article published on 21 February 2008

Evaluation of Multiple Biomarkers of Cardiovascular Stress for Risk Prediction and Guiding Medical Therapy in Patients With Stable Coronary Disease ⬇️

scientific article published on December 16, 2011

Evaluation of the National Cholesterol Education Program Adult Treatment Panel III algorithm for selecting candidates for statin therapy: insights from the A to Z trial

scientific article (publication date: 15 September 2006)

Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT).

scientific article published on July 2010

Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease

scientific article

Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial.

scientific article published on 25 June 2009

HMG CoA Reduction in Patients with Average Cholesterol Concentrations ⬇️

scientific article published on April 25, 2011

Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial

scientific article published on 10 July 2019

Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry

scientific article published on 21 June 2005

Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum

scientific article published on 12 February 2018

Hemoglobin Stability in Patients With Anemia, CKD, and Type 2 Diabetes: An Analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) Placebo Arm

article

High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial

scientific article published on 31 January 2008

Hyporesponsiveness to Darbepoetin Alfa in Patients With Heart Failure and Anemia in the RED-HF Study (Reduction of Events by Darbepoetin Alfa in Heart Failure): Clinical and Prognostic Associations

scientific article published in February 2018

Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions

scientific article published on 29 January 2020

Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure

scientific article (publication date: 12 October 2005)

Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction).

scientific article published in April 2014

Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme

scientific article published on 14 April 2008

Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure

scientific article published on 11 November 2008

Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program

scientific article published on 29 October 2007

Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy

scientific article published on 13 November 2007

Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease

scientific article

Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus

scientific article published in October 2017

Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure

article

Influence of albuminuria on cardiovascular risk in patients with stable coronary artery disease

scientific article published on 19 November 2007

Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients

scientific article

Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction

scientific article published on 17 October 2014

Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction

scientific article

International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction

scientific article published on 18 November 2014

Irbesartan in Patients with Atrial Fibrillation ⬇️

scientific article published on March 10, 2011

Left ventricular assessment in myocardial infarction: the VALIANT registry

scientific article (publication date: 10 October 2005)

Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program

scientific article

Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: The VALIANT experience

Longitudinal and circumferential strain rate, left ventricular remodeling, and prognosis after myocardial infarction

scientific article published on November 2010

Maximizing scientific knowledge from randomized clinical trials

scientific article published on June 2010

Mechanical dyssynchrony after myocardial infarction in patients with left ventricular dysfunction, heart failure, or both

scientific article

Mechanisms and predictors of mitral regurgitation after high-risk myocardial infarction

scientific article

Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease

scientific article published on 04 March 2019

Mitral regurgitation in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: prognostic significance and relation to ventricular size and function

scientific article published on 24 January 2007

Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials

scientific article published on 18 October 2004

New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment

scientific article published on 27 March 2017

New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes

scientific article

Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial

scientific article published on 13 September 2004

Opposing effects of β blockers and angiotensin-converting enzyme inhibitors on development of new-onset diabetes mellitus in patients with stable coronary artery disease

scientific article

Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or both

scientific article published on 26 July 2010

Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme

scientific article published in June 2005

Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT)

Peripheral artery disease and outcomes after myocardial infarction: an individual-patient meta-analysis of 28,771 patients in CAPRICORN, EPEHESUS, OPTIMAAL and VALIANT.

scientific article published on 26 November 2012

Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction

article

Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program

scientific article published on 05 February 2009

Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: An analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT)

article

Predictors of heart failure in patients with stable coronary artery disease: a PEACE study

scientific article

Predictors of mortality and morbidity in patients with chronic heart failure

scientific article

Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial

scientific article published on 23 October 2009

Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study

scientific article published on 28 February 2008

Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme

scientific article published on 20 February 2007

Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality

scientific article

Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes

scientific article published on 25 September 2017

Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program

scientific article published on 01 July 2006

Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction

scientific article published on 28 February 2006

Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study

scientific article

Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program

scientific article published on 2 November 2014

Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease

scholarly article by Marc S Sabatine et al published 27 March 2007 in Circulation

Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial

scientific article

Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease

scientific article

Race and ethnicity influences on cardiovascular and renal events in patients with diabetes mellitus.

scientific article published on 22 May 2015

Racial analysis of patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction treated with valsartan, captopril, or both

scientific article published in May 2008

Rationale—Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease

article

Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank

scientific article

Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction

scientific article (publication date: 23 September 2004)

Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure

scientific article published on 27 January 2015

Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)–Added trial

article by John McMurray et al published May 2006 in American Heart Journal

Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial

scientific article published on 26 June 2006

Renal function as a predictor of outcome in a broad spectrum of patients with heart failure

scientific article published in February 2006

Renal function estimation and Cockroft-Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart 'OMics' in AGEing (HOMAGE) and the high-risk myoc

scientific article

Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).

scientific article published in August 2005

Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme

scientific article published in June 2006

Response to Letter Regarding Article, “Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure”

Response to Letter Regarding Article, “Pathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both”

Response to The J-Point Revisited

Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials

scientific article

Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W).

scientific article published on 6 March 2008

Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus

scientific article published on 29 May 2017

Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial

scientific article (publication date: 7 July 2004)

Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project

scientific article published in May 2002

Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment

scientific article published on September 2016

Sex Differences in Clinical Characteristics and Prognosis in a Broad Spectrum of Patients With Heart Failure

article

Site selection for heart failure clinical trials in the USA.

scientific article published in July 2015

Streamlining cardiovascular clinical trials to improve efficiency and generalisability

scientific article published on 28 April 2017

Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation

scientific article published in February 2018

Sudden Death in Patients with Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both

article

Survival with cardiac-resynchronization therapy in mild heart failure

scientific article published on 30 March 2014

The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).

scientific article published on 26 January 2006

The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality

scientific article published in August 2008

The impact of kidney function on outcomes following high risk myocardial infarction: findings from 27 610 patients

scientific article published on 6 December 2013

The inter-relationship of diabetes and left ventricular systolic function on outcome after high-risk myocardial infarction

scientific article published on November 2010

Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)

scientific article published on 19 December 2018

Treatment of anemia with darbepoetin alfa in systolic heart failure

scientific article published on 10 March 2013

Usefulness of Right Ventricular Fractional Area Change to Predict Death, Heart Failure, and Stroke Following Myocardial Infarction (from the VALIANT ECHO Study)

article

Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).

scientific article

VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context

scientific article published in August 2003

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

scientific article published on 10 November 2003

Ventricular remodeling does not accompany the development of heart failure in diabetic patients after myocardial infarction

scientific article

Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme

scientific article

Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?

scientific article

Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme

scientific article

Paulina is supported by:

About Paulina

Help